{
    "nctId": "NCT00092196",
    "briefTitle": "Study of MK0869 for the Prevention of Chemotherapy-Induced Nausea and Vomiting (0869-071)(COMPLETED)",
    "officialTitle": "Open-label Extension to: A Randomized, Double-Blind, Parallel-Group Study Conducted Under In-House Blinding Conditions to Determine the Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Moderately Emetogenic Chemotherapy",
    "overallStatus": "COMPLETED",
    "conditions": "Nausea, Vomiting, Breast Neoplasms",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 820,
    "primaryOutcomeMeasure": "Safety and tolerability",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patient with a diagnosis of breast cancer requiring treatment with non-cisplatin moderately emetogenic chemotherapy.\n* Patient must have completed participation in the main study for this protocol.\n\nExclusion Criteria:\n\n* Patient has a central nervous system malignancy.\n* Patient will receive radiation to the abdomen or pelvis.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}